DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
“ - 2 ” - 2 Amgen - 1 Horizon’s - 1 Thgil - 1 Breen - 1 Thgil — - 1 Tommy Wiseau - 1
Top related locs:
New York Northern District Northern District of Illinois West Hollywood Calif Las Vegas Chicago Russia
Top related orgs:
New - 1 New York CNN - 1 Federal Trade Commission - 1 Horizon Therapeutics - 1 Court - 1 Northern - 1 Northern District of - 1 FTC - 1

Search resuls for: "Horizon’s"


9 mentions found


☆ Amgen settles with the FTC over $28 billion deal
  + stars: | 2023-09-01 | by ( Eva Rothenberg | ) edition.cnn.com   time to read: +2 min
In May, the FTC filed a complaint in the US District Court for the Northern District of Illinois to stop the deal from going ahead, alleging that it was anti-competitive. The lawsuit involved Horizon’s Tepezza, used to treat thyroid eye disease, and Kystexxa, used to treat chronic refractory gout. The FTC’s concern was that, by acquiring these products, Amgen would stifle competition by making it harder for consumers to have access to cheaper medicines if they were developed by competitors. It also needs to gain approval from the FTC before acquiring any other companies that manufacture these types of medicines. The two companies are expected to finalize the merger later this year, according to Amgen.
Persons: Amgen, Horizon’s, “ Organizations: New, New York CNN, Federal Trade Commission, Horizon Therapeutics, Court, Northern, Northern District of, FTC Locations: New York, Northern District, Northern District of Illinois
☆ What Distinguishes a Neil Breen Film? Neil Breen.
  + stars: | 2023-08-07 | by ( Rumsey Taylor | More About Rumsey Taylor | ) www.nytimes.com   time to read: +3 min
All of Breen’s films seem clearly to mean something, and watching them, one’s suspension of disbelief is constantly threatened by strange directorial choices. “Pass-Thru” culminates in his darkest sequence, with Thgil — another of the messianic aliens in which Breen specializes — walking toward the horizon’s vanishing point. “Fateful Findings,” which I and many others consider Breen’s most deranged film, exemplifies the tonal stiltedness and libertarian rage that pervades his work. For many audiences the natural response to Breen’s films is laughter. Breen plays a double role, twins Cale and Cade, bestowed at birth with superhuman powers and pitted against each other with potentially world-changing consequences.
Persons: Thgil, Breen, Thgil —, “, ”, Tommy Wiseau, Ed Wood, Wood, Cale, Cade Organizations: Media, West Coast Locations: West Hollywood, Calif, Las Vegas, Chicago
☆ Ukraine Recovery Conferece: War-torn economy needs private investors to rebuild
  + stars: | 2023-06-21 | by ( Hanna Ziady | ) edition.cnn.com   time to read: +5 min
Ukraine faces an enormous fundraising challenge, and it’s one that governments and development finance institutions won’t be able to meet without help from private investors. The Ukraine Development Fund is still in the planning stages and is not expected to launch until the conflict ends. But it faces a crucial test Wednesday, when it will canvas support from governments and investors attending the London conference. Attracting private investmentThe Ukraine Development Fund aims to raise so-called concessionary capital from governments and development finance institutions, and then use that to attract private investment. Sunak also unveiled a “war-risk insurance” framework Wednesday, backed by Group of Seven countries, which will help limit potential losses faced by private investors in Ukraine.
Persons: London CNN —, Rishi Sunak’s, Antony Blinken, Sergei Chuzavkov, Volodymyr Zelensky, Stefan Weiler, JPMorgan’s, Weiler, It’s, ”, Brandon Hall, ” Hall, Yan Dobronosov, ” Zelensky, Sunak, ” Sunak, Lenna Koszarny, — Jo Shelley Organizations: London CNN, Conference, Citi, Sanofi, Philips, Bank, World Bank, BlackRock, JPMorgan, Ukraine Development Fund, CNN, Fund, London, BlackRock’s, Group of, Private, Horizon Locations: Russia, Ukraine, London, United States, Russian, Kyiv, Ukrainian, Europe, East, Africa, Kupiansk
☆ FTC to block Amgen's $27.8 billion deal for Horizon Therapeutics - source
  + stars: | 2023-05-16 | by ( ) www.reuters.com   time to read: +2 min
May 15 (Reuters) - The U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc's (AMGN.O) $27.8 billion deal to buy Horizon Therapeutics PLC (HZNP.O), a person familiar with the matter told Reuters. Amgen struck a deal last year to buy Horizon to strengthen its rare diseases drugs portfolio. Senator Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the FTC earlier this year expressing her concerns about pharmaceutical deals including the Amgen purchase of Horizon. The Democratic Senator said both Amgen and Horizon Therapeutics "have engaged in brazen price increases," including on Amgen's Enbrel for arthritis and Horizon’s Krystexxa, a gout medication. The deal would give Amgen two fast-growing drugs, the thyroid eye disease treatment Tepezza and Krystexxa.
☆ First Horizon stock tumbles 50% after TD Bank merger collapses
  + stars: | 2023-05-04 | by ( David Goldman | ) edition.cnn.com   time to read: +3 min
New York CNN —First Horizon and TD Bank have called off a $13 billion deal that would have formed America’s sixth-largest bank, adding to the turmoil sweeping the country’s regional lenders. But regional banks have been losing the confidence of investors and customers since the March collapse of Silicon Valley Bank and Signature Bank. On Monday, a third regional bank, First Republic, failed and JPMorgan purchased most of its assets. Other regional bank stocks have tumbled in recent days after First Republic’s failure. Customers had been moving their money to bigger banks, leaving some regional banks without the cash they need to pay for withdrawals.
☆ Elizabeth Warren leads cavalry into deal battles
  + stars: | 2023-03-07 | by ( Jonathan Guilford | ) www.reuters.com   time to read: +3 min
It would be the third curious regulatory intervention in recent weeks, each encouraged by Democratic Senator Elizabeth Warren. In a September letter to Transportation Secretary Pete Buttigieg, Warren argued that the DOT should use its own tools, specifically in the Spirit situation. UnitedHealth (UNH.N) beat back a federal lawsuit against its plan to buy Change Healthcare; Facebook owner Meta Platforms (META.O) shrugged off an FTC attempt to stop its purchase of fitness app developer Within. JetBlue says it built time for a lawsuit into the Spirit merger agreement. As the senator charges up the competition cavalry, dealmakers may have to redraw their battle plans.
☆ Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals
  + stars: | 2023-01-26 | by ( ) www.reuters.com   time to read: +2 min
Warren said that both Amgen and Horizon Therapeutics "have engaged in brazen price increases," including on Amgen's Enbrel for arthritis and Horizon’s Krystexxa, a gout medication. She noted that the FTC had settled with Indivior and its former parent over its attempt to protect its monopoly of the opioid addiction treatment Suboxone. Indivior makes Sublocade -- a slow-release treatment for opioid addiction that is administered monthly. "The FTC should strongly consider Indivior's history of anti-competitive and deceptive practices when evaluating howIndivior might behave after this potential transaction is completed," wrote Warren. Warren noted that the FTC, which has long focused on healthcare mergers, said in 2021 that it would prioritize pharmaceutical acquisitions.
☆ First Test for Amgen: Fix Horizon’s Growth Problem
  + stars: | 2022-12-12 | by ( David Wainer | ) www.wsj.com   time to read: 1 min
The crown jewel in Amgen ’s $28 billion acquisition of Horizon Therapeutics is the drug Tepezza for thyroid eye disease, a rare condition that causes swelling and damage to the tissues around the eye. It is the only drug approved in the U.S. for the condition and is generating close to $2 billion in annualized sales. Horizon in November upped its guidance for the treatment, predicting expansion abroad and growth in the U.S. will help the drug fetch more than $4 billion in peak sales. The raised guidance was seen by many on Wall Street as a sign the company was gearing up for a sale. One immediate challenge: Sales of the treatment have plateaued in recent quarters, raising the question of whether Horizon’s numbers are realistic.
☆ Amgen’s $28 bln deal is a reasonable gamble
  + stars: | 2022-12-12 | by ( Robert Cyran | ) www.reuters.com   time to read: +3 min
NEW YORK, Dec 12 (Reuters Breakingviews) - Biotechnology deals are always a gamble, and, on the face of it, Amgen’s (AMGN.O) $28 billion purchase of Horizon Therapeutics (HZNP.O) looks both risky and pricey. Investors in the $150 billion drug buyer should give it the benefit of the doubt. Amgen is largely buying Horizon for a drug named Tepezza, which helps a thyroid disease that affects eyesight. Sales in Alexion’s drug this year should be $7 billion, a 16% jump from where they were when AstraZeneca bought it. If Amgen similarly helps Horizon, its deal will look like a reasonable wager.
0 next >>
Total: 9